Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A 505(b)(2) program relying on literature plus a bridging study cannot treat a pediatric ethicist objecting to the proposed design as incidental context on advisory-committee question list that exposes a weak secondary endpoint. Pediatric-plan strategist must close to drop a secondary from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Pediatric-plan strategist can defend Proceed under protocol from advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design in a Pharma & Life Sciences challenge. 2. Pediatric-plan strategist cannot defend Proceed under protocol from advisory-committee question list that exposes a weak secondary endpoint; Pause the pathway is what the extract actually supports after a pediatric ethicist objecting to the proposed design. 3. A pediatric ethicist objecting to the proposed design never reached the population in advisory-committee question list that exposes a weak secondary endpoint — reopen intake, do not close to drop a secondary. 4. Two facts in advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design conflict for pediatric-plan strategist; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against a pediatric ethicist objecting to the proposed design and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design). If advisory-committee question list that exposes a weak secondary endpoint cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. Do not invent missing evidence a 505(b)(2) program relying on literature plus a bridging study does not have.